Cardiff Lexington Announces Second Quarter 2026 Financial Results

Wednesday, August 12, 2026 · 8:00 AM ET ACCESS Newswire

LEXINGTON, KY / ACCESS Newswire / August 12, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX), a publicly traded healthcare services holding company focused on orthopedic, spine, and pain management platforms, today announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 with the U.S. Securities and Exchange Commission.

Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "During the first half of 2026, we continued to execute on our long-term strategy to establish Nova Ortho and Spine as a leading healthcare network and provide best-in-class care to a severely underserved patient population. During the second quarter, we opened our 12^th Nova Ortho and Spine location in Tallahassee, Florida, representing a strategic metropolitan location with high patient volume and visibility, and we continue to strengthen our team with the addition of leading doctors, nurses, and operators. We remain confident that we're fulfilling a critical healthcare need in a highly attractive geographic market, and we see this as a strong opportunity for continued growth.

"While execution has been strong, the first half of the year has not been without its challenges. Year-to-date revenue was down compared to last year, and though we saw an increase in both new patients and billed surgical procedures in the year to date period, we recognized a lower implicit realization rate on patient case claim settlements during the first half of the year. Despite this, gross profit in the first half was strong at 57%, and we realized a slight adjusted non-GAAP EBITDA loss of $14,000 compared with non-GAAP adjusted EBITDA of $1.3 million in the first half of 2025.

"We're seeing significant demand for our services, however, working capital constraints have limited our ability to capitalize on opportunities and has required us to access capital at high costs. We continue to evaluate opportunities for debt restructuring and equity infusions to offset this current cost of capital. That said, we have strong brand recognition in the markets we serve, and we remain committed to driving execution and continuing to provide the best available care to our patients across our network of Nova Ortho and Spine locations throughout Florida and Georgia, where there is strong demand.

"Looking ahead, our focus is on returning our business to historical levels of performance while driving long-term, sustained value for our shareholders. Over the course of several years, we have proven that this model can deliver consistent revenue growth and high returns on invested capital, and we remain confident in our ability to build on that as we enhance our access to working capital and pursue the many opportunities available to us in this exciting market. We're encouraged by what's ahead, and we thank you for your continued support and belief in Cardiff Lexington," Mr. Cunningham concluded.

Financial tables are below, and the Company's Quarterly Report on Form 10-Q is available on the SEC's website at www.sec.gov and on the Investor Relations section of the Company's website.

Conference Call

Cardiff Lexington will hold a conference call and webcast for investors today, August 12, 2026, at 11:00 a.m. Eastern Time.

Shareholders and interested parties may participate in the conference call by dialing (888) 506-0062 and international participants should dial (973) 528-0011 and use access code: 876877. The call and the accompanying slide deck will also be webcast at:

https://www.webcaster5.com/Webcast/Page/3131/54266

An online archive of the webcast will be available at the above webcast link. A replay of the conference call will be available one hour after completion of the call until Wednesday, August 26, 2026, by dialing (877) 481-4010 and international participants should dial (919) 882-2331. All callers must use access code 54266 to access the replay.

-----

About Cardiff Lexington Corporation:

Cardiff Lexington Corporation is a publicly traded healthcare services holding company focused on building a regional and national platform in orthopedic, spine, and pain management markets. Through its operating subsidiaries, including Nova Ortho and Spine, the Company delivers a comprehensive suite of services including diagnostics, interventional pain management, surgical coordination, and specialty care.

The Company's strategy is centered on disciplined capital deployment, operational efficiency, and scalable growth through acquisitions and strategic partnerships within highly fragmented healthcare markets.

FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.

Use of Non-GAAP Financial Measures

Cardiff Lexington Corporation prepares its consolidated financial statements in accordance with United States generally accepted accounting principles ("GAAP"). In addition to GAAP disclosures, this document contains financial information and measures considered to be "non-GAAP". These non-GAAP measures can be used in order to gain a more complete and accurate understanding of the Company's financial condition and results. Non-GAAP financial measures should be considered in conjunction with, and not as a substitute to GAAP financial measures.

Contact:

Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705

IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200

CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 AND 2025
(UNAUDITED)

	Three Months Ended June 30,						Six Months Ended June 30,
	2026			2025			2026			2025
REVENUE	$	2,159,557		$	2,789,007		$	4,381,837		$	5,704,574
COST OF SALES		977,242			1,093,748			1,881,467			2,168,782
GROSS PROFIT		1,182,315			1,695,259			2,500,370			3,535,792

OPERATING EXPENSES
Depreciation expense		253			763			846			4,128
Loss on disposal of fixed assets		-			-			-			12,593
Share-based compensation		366,939			97,500			1,031,135			97,500
Selling, general and administrative		1,359,766			987,319			2,524,191			2,267,960
Total operating expenses		1,726,958			1,085,582			3,556,172			2,382,181

(LOSS) / INCOME FROM OPERATIONS		(544,643	)		609,677			(1,055,802	)		1,153,611

OTHER (EXPENSE) INCOME
Other income (expense)		-			-			10,081			(1,597	)
Derivative liability gain (loss) on issuance and changes in fair value		226,049			-			(442,772	)		-
Interest expense		(2,137,419	)		(1,836,072	)		(4,048,156	)		(2,829,186	)
Amortization of debt discounts		(22,893	)		-			(34,331	)		-
Total other expense		(1,934,263	)		(1,836,072	)		(4,515,178	)		(2,830,783	)

NET LOSS	$	(2,478,906	)	$	(1,226,395	)	$	(5,570,980	)	$	(1,677,172	)

PREFERRED STOCK DIVIDENDS	$	(282,900	)	$	(254,008	)	$	(555,359	)	$	(499,453	)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$	(2,761,806	)	$	(1,480,403	)	$	(6,126,339	)	$	(2,176,625	)

BASIC AND DILUTED LOSS PER SHARE	$	(0.18	)	$	(0.24	)	$	(0.41	)	$	(0.39	)

WEIGHTED AVERAGE SHARES OUTSTANDING - BASIC AND DILUTED *		15,265,398			6,191,240			14,863,185			5,651,634

*Shares outstanding for the three and six months ended June 30, 2025 have been restated for the 1-for-3 reverse stock split effective January 12, 2026. See Note 1. Summary of Significant Accounting Policies.

CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF JUNE 30, 2026 (UNAUDITED) AND DECEMBER 31, 2025

	June 30, 2026			December 31, 2025
ASSETS
Current assets
Cash	$	217,654		$	318,535
Accounts receivable, net		23,725,621			22,070,954
Prepaid and other current assets		352,603			203,876
Total current assets		24,295,878			22,593,365

Property and equipment, net		2,107			2,953
Land		540,000			540,000
Goodwill		5,666,608			5,666,608
Right of use - assets, net		105,726			214,858
Due from related party		4,979			4,979
Other assets		65,539			64,182
Total assets	$	30,680,837		$	29,086,945

LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY/(DEFICIT)
Current liabilities
Accounts payable and accrued expense	$	1,869,755		$	1,760,765
Accrued expenses - related parties		232,393			4,645,826
Accrued interest		769,180			707,574
Right of use - operating lease liabilities		108,980			178,524
Notes payable - current portion		15,717			125,774
Notes payable related parties - current portion		1,085,703			1,085,703
Line of credit		21,138,949			17,209,908
Convertible notes payable, net of debt discounts of $1,061,124 and $131,705, respectively - current portion		302,765			118,295
Derivative liabilities		1,087,129			-
Total current liabilities		26,610,571			25,832,369

Other liabilities
Operating lease liability - long term		-			42,976
Notes payable		137,115			138,773
Notes payable - related parties		350,000			-
Total liabilities		27,097,686			26,014,118

Mezzanine equity
Redeemable Series N Senior Convertible Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value $4.00, 0 and 1,037,311 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively		-			3,802,010
Redeemable Series X Senior Convertible Preferred Stock - 5,000,000 shares authorized, $0.001 par value, stated value of $4.00; 460,233 and 438,388 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively		1,827,857			1,740,478
Total Mezzanine Equity		1,827,857			5,542,488

Stockholders' equity/(deficit)
Series F-1 Preferred Stock - 50,000 shares authorized, $0.001 par value, stated value $4.00, 3,875 shares issued and outstanding at June 30, 2026 and December 31, 2025		15,500			15,500
Series L Preferred Stock - 400,000 shares authorized, $0.001 par value, stated value $4.00, 319,493 shares issued and outstanding at June 30, 2026 and December 31, 2025		1,277,972			1,277,972

Series N Senior Convertible Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value $4.00, 1,099,957 and 0 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively		4,052,591			-

Series Y Senior Convertible Preferred Stock - 1,500,000 shares authorized, $0.001 par value, stated value of $4.00, 1,122,091 and 1,067,878 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively		4,488,358			4,271,512
Common Stock: 300,000,000 shares authorized, $0.001 par value; 15,283,191 and 13,701,698 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively		15,283			13,702
Additional paid-in capital		77,763,975			72,021,848
Unearned stock-based compensation		(241,066	)		(579,215	)
Accumulated deficit		(85,617,319	)		(79,490,980	)
Total stockholders' equity/(deficit)		1,755,294			(2,469,661	)
Total liabilities, mezzanine equity and stockholders' equity/(deficit)	$	30,680,837		$	29,086,945

CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026, AND 2025
(Unaudited)

The following table reconciles Net income (loss) before discontinued operations (a GAAP financial measure) to EBITDA and Adjusted EBITDA (non-GAAP financial measures)

	For the Three Months Ended						For the Six Months Ended
	June 30,						June 30,
	2026			2025			2026			2025
EBITDA₍₁₎
Net loss before discontinued operations	$	(2,478,906	)	$	(1,226,395	)	$	(5,570,980	)	$	(1,677,172	)
Add:
Interest		2,137,419			1,836,072			4,048,156			2,829,186
Taxes		0			0			0			0
Depreciation		253			763			846			4,128
Amortization		22,893			0			34,331			0

EBITDA₍₁₎	$	(318,341	)	$	610,440		$	(1,487,647	)	$	1,156,142

Adjusted EBITDA ₍₂₎
EBITDA	$	(318,341	)	$	610,440		$	(1,487,647	)	$	1,156,142
Add:
Derivative liability gain (loss) on issuance and change in fair value		(226,049	)		0			442,772			0
Stock compensation expense for shares issued		366,939			97,500			1,031,135			97,500


Adjusted EBITDA₍₂₎	$	(177,451	)	$	707,940		$	(13,740	)	$	1,253,642

(1) EBITDA is a non-GAAP financial measure defined as Earnings Before Interest, Income Tax, Depreciation and Amortization.
(2) Adjusted EBITDA is a non-GAAP financial measure that is the sum of EBITDA plus non-recurring and non-cash charges.


Adjusted EBITDA excluding other non-recurring costs₍₃₎

Adjusted EBITDA	$	(177,451	)	$	707,940		$	(13,740	)	$	1,253,642
Add:
Scaling and restructuring costs for business growth		51,545			11,676			66,308			11,676
Acquisition related costs		138,652			1,445			217,805			58,079

Adjusted EBITDA excluding other non-recurring costs₍₃₎	$	12,746		$	721,061		$	270,372		$	1,323,397

(3) Adjusted EBITDA excluding other non-recurring costs is a non-GAAP financial measure that is the sum of Adjusted EBITDA plus other non-recurring costs.

SOURCE: Cardiff Lexington Corporation

View the original press release on ACCESS Newswire

← Back to CDIX news

CDIX Cardiff Lexington Corporation

Cardiff Lexington Announces Second Quarter 2026 Financial Results